ABO-incompatible liver transplantation for liver failure

National Medical Journal of China

Volumn 87, Issue 40, 2007, Pages 2833-2836

  Yang, Yang ^a   Xu, Chi ^a   Chen, Ying Hua ^a   Lu, Min Qiang ^a   Cai, Chang Jie ^a   Li, Hua ^a   Wang, Gen Shu ^a   Yi, Shu Hong ^a   Zhang, Jian ^a   Yi, Hui Min ^a   Zhang, Jun Feng ^a   Jiang, Nan ^a   Zhao, Hui ^a   Li, Xi ^a   Li, Min Ru ^a   Chen, Gui Hua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

ABO compatibility; Liver failure; Liver transplantation; MELD

Indexed keywords

CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGED; ARTICLE; BILIARY TRACT DISEASE; BLOOD GROUP ABO INCOMPATIBILITY; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; EMERGENCY SURGERY; FEMALE; FOLLOW UP; HUMAN; INFECTION; INFECTION RATE; KIDNEY FAILURE; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; BLOOD GROUP INCOMPATIBILITY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 38549133458     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Vaquero J, Blei AT. Etiology and management of fulminant hepatic failure. Curr Gastroenterol Rep, 2003, 16:39-47.
2. Koukoutsis I, Bellagamba R, Tamijmarane A, et al. Outcomes after identical and compatible orthotopic liver tranaplantation for fulminant hepatic failure: a single center experience in UK. Transpl Int, 2007, 23:45-55.
3. Lo CM, Shaked A, Busuttil RW, et al. Risk factors for liver transplantation across the ABO barrier. Transplantation,1994, 58: 543-547.
4. Chinese source.
5. Salerno F, Merli M, Cazzaniga M, et al. MELD score is better than Child-Pugh score in predicting 3-month survival of patients undergoing transjugular intrahepatic portosystemic shunt. J Hepatol, 2002, 36: 494-500.
6. Trotter JF, Osgood MJ. MELD scores of liver transplant recipients according to size of waiting list: impact of organ allocation and patient outcomes. JAMA, 2004, 291:1871.
7. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology, 2001, 33:464-470.
8. Chinese source.
9. Douglus UH, Annie HF, Murid HA, et al. ABO-Incompatible liver transplantation with no immunolog:ical graft losses using total plasma exchanuge, splenectomy, and quadruple immunosuppression: evidence for accommodation. Liver transpl, 2003, 9:22-30.
10. Ekberg H, Backman L, Tufveson G, et al. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Transpl Int, 2000,13:151-159.
11. Luis Sanchez-Urdazpal, Kenneth PB, Gregory JG, et al. Increased bile duct complications in liver transplantation across the ABO barrier. Ann Surg,1993, 218:152-158.
12. Egawa H, Uemoto S, Inomata Y, et al. Biliary complications in pediatric living related liver transplantation. Surgery, 1998,124: 901-910.
13. Farges O, Kalil AN, Samuel D, et al. The use of ABO-incompatible grafts in liver transplantation: a life-saving procedure in highly selected patients. Transplantation, 1995,59:1124-1133.